Загрузка...
Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
BACKGROUND: Belimumab is a recombinant, human, IgG1λ monoclonal antibody that targets B-lymphocyte stimulator. The intravenous formulation is indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Belimumab has been formulated for subcutaneous (SC) administr...
Сохранить в:
| Опубликовано в: : | Lupus |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5054300/ https://ncbi.nlm.nih.gov/pubmed/27072354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203316642309 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|